Brelovitug Clears the First Pivotal HDV Gate

Company Mirum Pharmaceuticals Event Type Phase 3 Results Modality Monoclonal Antibody Asset Brelovitug Target Hepatitis B Surface Antigen Disease Area Chronic Hepatitis Delta Virus Infection Summary Mirum reported that brelovitug met the Phase 3 AZURE-1 primary endpoint in treatment-naive chronic hepatitis delta virus infection. At…